FYB.DE Formycon XETRA intraday +5.33% 02 Apr 2026: earnings 15:30 key catalyst

The FYB.DE stock is trading at €18.96, up 5.33% intraday as investors position ahead of Formycon AG’s earnings announcement on 02 Apr 2026 at 15:30 UTC. The move comes with low volume of 5,312 shares versus an average of 17,752, suggesting selective buying. Today’s reaction ties directly to pipeline updates and near-term revenue signals for the biotechnology company on XETRA in Germany.

Earnings timing and what to expect from FYB.DE stock

Formycon’s earnings call is scheduled for 02 Apr 2026 at 15:30 UTC. Management may update guidance on clinical progress for FYB201, FYB202 and FYB203 and licensing revenue timing. One clear near-term catalyst is any clarity on commercialization deals or milestone payments that would change revenue visibility and cash flow.

Valuation and key financial metrics for FYB.DE stock

Formycon trades at €18.96 with EPS -9.67 and PE -1.96, reflecting negative earnings. Book value per share is €23.13 and price-to-book is 0.82, which signals price below book value. Market cap stands at €335,078,184.00 and the 50-day/200-day averages are €21.33 and €23.92 respectively, showing a medium-term downtrend relative to current price.

Operational strength and cash flow signals

Formycon reports operating cash flow per share €0.82 and free cash flow per share €0.78, indicating positive cash generation despite losses at the net income line. The company’s current ratio is 1.54 and debt-to-equity is 0.02, suggesting manageable leverage for a clinical-stage biotech. Watch working capital and receivables ahead of the report for any sales recognition shifts.

Technical and trading context for FYB.DE stock

Intraday range today is €18.26–€19.24 with average true range €1.09. Momentum indicators show RSI 46.98 and MACD histogram 0.18, implying neutral momentum with a slight short-term bullish tilt. On the charts, support near the 50-day average €21.33 and resistance at the year high €31.30 frame scenarios for post-earnings moves.

Meyka AI grade and model forecast for FYB.DE stock

Meyka AI rates FYB.DE with a score out of 100: 65.31/100 — Grade B, Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly price of €17.49 and a yearly price of €9.50. Compared with the current price €18.96, the monthly projection implies -7.76% downside and the yearly projection implies -49.87% downside. Forecasts are model-based projections and not guarantees.

Risks, opportunities and sector context for FYB.DE stock

Key risks include clinical setbacks, delayed licensing revenue, and continued negative EPS. Opportunities include successful Phase III readouts for FYB202/FYB203 and new partnership deals that would improve revenue visibility. In the Healthcare sector, peers trade at higher price-to-book multiples, so Formycon’s relative valuation may rerate on positive clinical or commercial news.

Final Thoughts

Formycon AG (FYB.DE) is trading at €18.96 on XETRA as intraday buyers position ahead of the 02 Apr 2026 15:30 earnings update. The stock shows a short-term pickup on thin volume but still sits below its 50- and 200-day averages. Our scenario targets: a conservative price target of €12.50 (bear), a base case €20.00, and a bull case €30.00, anchored to milestone visibility and commercialization timing. Meyka AI’s forecast model projects €17.49 for the month and €9.50 for the year; the monthly figure implies -7.76% downside from today’s price while the yearly figure implies -49.87% downside. These projections, combined with the company’s book value €23.13 per share and cash flow metrics, frame a risk-reward profile driven by binary clinical and licensing events. Investors should watch the earnings call for revenue recognition changes and management commentary on partnering timelines. For a quick reference see Formycon on Meyka AI: https://meyka.ai/stocks/FYB.DE and read the latest company metrics on Reuters and peer comparisons on Investing.com. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.